AI Personalized Aging Rate Intervention Platform AgeClock Wins EMA Approval: A Full-Spectrum Anti-Aging Approach From Telomeres to Metabolomics
UK-based Insilico Medicine's AgeClock platform has received EMA approval, integrating telomere length, epigenetic clocks, and metabolomic data to generate personalized anti-aging intervention plans for each individual.
AI Personalized Aging Rate Intervention Platform AgeClock Wins EMA Approval: A Full-Spectrum Anti-Aging Approach From Telomeres to Metabolomics
AgeClock, the AI aging intervention platform developed by UK-based Insilico Medicine, received approval from the European Medicines Agency (EMA) on June 15 as a Class II medical device. The platform integrates telomere length measurement, DNA methylation clocks, metabolomic analysis, and proteomic data to precisely assess an individual's biological age (as distinct from chronological age) and generate personalized anti-aging intervention plans.
Among the first 5,000 users, those who followed the AgeClock protocol for more than six months experienced an average reversal of 2.3 years in biological age. The platform's recommended interventions include specific exercise prescriptions, nutritional supplementation plans, and sleep optimization strategies — no prescription medications are involved. AgeClock's annual subscription fee is 499 pounds.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.